A groundbreaking study has revealed a 30% reduction in preeclampsia risk, offering a glimmer of hope to expectant mothers. But here's where it gets controversial: the intervention, which involves planned early-term births based on risk assessment, challenges conventional wisdom and raises intriguing questions.
While existing interventions, such as prophylactic aspirin, have proven effective in reducing preterm preeclampsia, they fall short when it comes to term preeclampsia. This is where the study steps in, presenting a personalized approach to near-term preeclampsia risk assessment.
Among over 8,000 women, the results speak for themselves: term preeclampsia occurred in a significantly lower percentage of those who underwent risk assessment and planned early-term birth compared to the control group. And this is the part most people miss: the study not only reduced the incidence of preeclampsia but also showed no significant differences in emergency cesarean births and neonatal care unit admissions.
Dr. Kypros Nicolaides, a leading expert in the field, emphasizes the importance of these findings, stating that a 30% reduction in preeclampsia is "very important" and represents a greater impact than what aspirin can achieve for preterm preeclampsia.
Preeclampsia, a complication affecting approximately 3% of pregnancies, is a serious concern, particularly as three-quarters of cases occur at term gestational age, leading to a significant number of maternal and fetal deaths or major morbidity.
The study utilized the Fetal Medicine Foundation's competing-risks model to assess the risk of late preterm and term preeclampsia at 35 to 36 weeks' gestation. This model, which considers various maternal factors and biomarkers, identifies around 70% of women who subsequently develop preeclampsia.
Previous research had hinted at the potential benefits of planned delivery at term, and the current study aimed to investigate whether this strategy, combined with risk-stratified early-term birth, could further reduce the incidence of preeclampsia.
In the intervention group, women with a higher risk of preeclampsia, as determined by the FMF model, were offered early-term birth, with the timing tailored to their individual risk level. For instance, birth was planned at 37 weeks for those with a higher risk, while those with a lower risk were offered birth at 39 weeks.
The study's authors highlight that this is the first trial to demonstrate the effectiveness of a personalized approach to near-term preeclampsia risk assessment in reducing disease incidence among the maternity population.
In an accompanying editorial, Dr. Susan Walker and colleagues noted that while previous trials, such as HYPITAT, had shown promising results in reducing maternal morbidity, an effective triage strategy to identify those at the highest risk was lacking. The current study fills this gap, providing compelling evidence of maternal benefit.
Walker and her team further emphasize the potential long-term benefits of this intervention, highlighting the increased risks of hypertension, cardiovascular disease, and stroke that women face following hypertensive pregnancies. They also suggest that implementing the PREVENT-PE package in low-resource countries could have a far greater impact on human health than its application in the U.K.
The PREVENT-PE trial was a two-arm, parallel-group, open-label study conducted at two maternity hospitals in the U.K. between May 2023 and June 2024. The study included 8,094 women aged 16 and older with singleton pregnancies and live fetuses without major anomalies. The participants' characteristics were well-balanced between the two groups, ensuring a fair comparison.
While the study provides valuable insights, the authors acknowledge some limitations. The study was conducted at sites in the U.K. where a 36-week birth-plan scan is part of standard care, which may not reflect the situation in other healthcare settings. Additionally, the study only included singleton pregnancies, leaving the applicability of the findings to multifetal pregnancies uncertain. Lastly, the incidence of preeclampsia and gestational hypertension was higher than expected in both groups, and the authors' conservative estimate of preeclampsia incidence may have led to a smaller-than-anticipated reduction in incidence.
Despite these limitations, the study's findings offer a promising new approach to reducing preeclampsia risk. As we delve deeper into the implications of this research, one question remains: How can we ensure that this potentially life-saving intervention reaches those who need it most, especially in low-resource settings?
